Skip to content

Released Nov 10, 2022, after the close

10-Q filed Nov 10, 2022, 41 days after period end · 0000950170-22-024436

Q3 2022 · 10-Q
Revenue—
Net Income-$1.17MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$1.91N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$1,199,464N/M
Operating Cash Flowderived-$1,731,418N/M

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020
Net Income-$1.17M-$3.04M-$868.00
EPS Diluted-$1.91-$0.48$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR